| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/12/2022 | -31.79% | Piper Sandler | $31 → $24 | Downgrades | Neutral → Underweight |
| 10/12/2022 | 13.68% | Goldman Sachs | $45 → $40 | Maintains | Buy |
| 06/23/2022 | 22.21% | Goldman Sachs | $50 → $43 | Maintains | Buy |
| 06/14/2022 | 2.32% | Piper Sandler | $40 → $36 | Maintains | Neutral |
| 05/04/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 04/07/2022 | 8% | Piper Sandler | $43 → $38 | Maintains | Neutral |
| 02/09/2022 | 42.11% | Raymond James | $55 → $50 | Maintains | Outperform |
| 11/03/2021 | 56.32% | Raymond James | $60 → $55 | Maintains | Outperform |
| 05/05/2021 | 70.53% | Raymond James | $48 → $60 | Maintains | Outperform |
| 02/10/2021 | — | Raymond James | Downgrades | Strong Buy → Outperform | |
| 11/20/2020 | 47.79% | Goldman Sachs | → $52 | Upgrades | Neutral → Buy |
| 11/04/2020 | 19.37% | Piper Sandler | $39 → $42 | Maintains | Neutral |
| 11/04/2020 | 36.42% | Raymond James | $45 → $48 | Maintains | Strong Buy |
| 08/05/2020 | 27.9% | Raymond James | $41 → $45 | Maintains | Strong Buy |
| 07/28/2020 | 16.53% | Raymond James | $38 → $41 | Maintains | Strong Buy |
| 05/28/2020 | 8% | Raymond James | $32 → $38 | Maintains | Strong Buy |
| 05/18/2020 | -14.74% | SunTrust Robinson Humphrey | $27 → $30 | Maintains | Hold |
| 05/14/2020 | -9.05% | Raymond James | → $32 | Upgrades | Market Perform → Strong Buy |
| 05/06/2020 | -23.26% | SunTrust Robinson Humphrey | $29 → $27 | Maintains | Hold |
| 04/16/2020 | -17.58% | SunTrust Robinson Humphrey | $24 → $29 | Maintains | Hold |
| 04/15/2020 | -0.53% | Piper Sandler | $47 → $35 | Maintains | Neutral |
| 04/03/2020 | -31.79% | SunTrust Robinson Humphrey | $50 → $24 | Maintains | Hold |
| 11/19/2019 | 56.32% | Stifel | $52 → $55 | Downgrades | Buy → Hold |
| 10/30/2019 | — | SunTrust Robinson Humphrey | Downgrades | Buy → Hold | |
| 07/24/2019 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 10/29/2018 | 25.05% | Raymond James | → $44 | Downgrades | Strong Buy → Outperform |
| 05/31/2018 | — | Stifel | Upgrades | Hold → Buy | |
| 04/27/2018 | 30.74% | Credit Suisse | $51 → $46 | Maintains | Neutral |
What is the target price for Leggett & Platt (LEG)?
The latest price target for Leggett & Platt (NYSE: LEG) was reported by Piper Sandler on December 12, 2022. The analyst firm set a price target for $24.00 expecting LEG to fall to within 12 months (a possible -31.79% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Leggett & Platt (LEG)?
The latest analyst rating for Leggett & Platt (NYSE: LEG) was provided by Piper Sandler, and Leggett & Platt downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for Leggett & Platt (LEG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leggett & Platt, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leggett & Platt was filed on December 12, 2022 so you should expect the next rating to be made available sometime around December 12, 2023.
Is the Analyst Rating Leggett & Platt (LEG) correct?
While ratings are subjective and will change, the latest Leggett & Platt (LEG) rating was a downgraded with a price target of $31.00 to $24.00. The current price Leggett & Platt (LEG) is trading at is $35.19, which is out of the analyst's predicted range.